FLT3-ITD mutation

News alerts, weekly reports and conference planners

Entrez ID:

2322

Related biomarkers:

‹

›

Related tests:

LeukoStrat® CDx FLT3 Mutation Assay (6)

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine Resistant: B - Late Trials cytarabine Resistant : B	cytarabine Resistant: B - Late Trials cytarabine Resistant : B
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	HEC73543 Sensitive: C2 – Inclusion Criteria HEC73543 Sensitive : C2	HEC73543 Sensitive: C2 – Inclusion Criteria HEC73543 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: C3 – Early Trials FLT3 inhibitor Sensitive : C3	FLT3 inhibitor Sensitive: C3 – Early Trials FLT3 inhibitor Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	FF-10101 Sensitive: C3 – Early Trials FF-10101 Sensitive : C3	FF-10101 Sensitive: C3 – Early Trials FF-10101 Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	Sensitive: C4 – Case Studies Sensitive : C4	Sensitive: C4 – Case Studies Sensitive : C4
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	SGN-CD33A Sensitive: D – Preclinical SGN-CD33A Sensitive : D	SGN-CD33A Sensitive: D – Preclinical SGN-CD33A Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	bortezomib + verteporfin Sensitive: D – Preclinical bortezomib + verteporfin Sensitive : D	bortezomib + verteporfin Sensitive: D – Preclinical bortezomib + verteporfin Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D

FLT3-ITD mutation

Associations